This trial will evaluate the safety and effectiveness of the ACURATE Transfemoral Aortic Valve System for transcatheter aortic valve replacement (TAVR) in subjects with severe native aortic stenosis who are indicated for TAVR.
1 Primary · 0 Secondary · Reporting Duration: Participants will be followed for the duration of the trial, through 10 years.
1720 Total Participants · 4 Treatment Groups
Primary Treatment: ACURATE neo2™ Transfemoral TAVR System · No Placebo Group · N/A
Age Any Age · All Participants · 8 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: